MARKET

TLSA

TLSA

TIZIANA LIFE SCIENCES PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.580
+0.160
+3.62%
After Hours: 4.850 +0.27 +5.90% 17:55 10/26 EDT
OPEN
4.450
PREV CLOSE
4.420
HIGH
4.850
LOW
4.420
VOLUME
301.70K
TURNOVER
--
52 WEEK HIGH
12.17
52 WEEK LOW
0.6160
MARKET CAP
175.36M
P/E (TTM)
-17.2596
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Tiziana Life's (TLSA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Tiziana Life Sciences (TLSA).
Zacks · 4d ago
Selecta Biosciences and CareDx among healthcare gainers; Cytokinetics and ChromaDex among losers
Gainers: AgeX Therapeutics (AGE) +260%. Alphatec (ATEC) +36%. CareDx (CDNA) +19%. Selecta Biosciences (SELB) +16%. Tiziana Life Sciences (TLSA) +13%.Losers: Cytokinetics (CYTK) -44%. Taiwan Liposome (TLC) -18%. IMARA (IMRA) -7%. GenMark Diagnostics (GNMK) -6%. ChromaDex (CDXC) -5%.
Seekingalpha · 10/08 14:57
Ocular Therapeutix and American Well among healthcare gainers, ARCA biopharma and Axovant Gene Therapies among losers
Gainers: Taiwan Liposome (TLC) +36%. Ocular Therapeutix (OCUL) +21%. LogicBio Therapeutics (LOGC) +11%. American Well (AMWL) +11%. Tiziana Life Sciences (TLSA) +11%.Losers: Enlivex Therapeutics (ENLV) -12%. Aytu BioScience (AYTU) -12%. Xtant Medical (XTNT) -11%.
Seekingalpha · 10/07 14:54
Stock market ends otherwise strong week lower Friday as President Trump's coronavirus diagnosis stokes uncertainty
The three main U.s. stock benchmarks finished Friday in negative territory, but well off their lows, as investors parsed news that President Trump said he...
marketwatch.com · 10/02 20:11
Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
LONDON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- At the General Meeting of the Company (Nasdaq: TLSA / AIM: TILS) held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed. The anticipated timetable for the demerger of Accustem Sciences Limited (to be re-registered as Accustem Sciences
GlobeNewswire · 10/02 11:00
Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report
LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with
GlobeNewswire · 09/25 07:00
Tiziana Life Sciences plc: Publication of Research Note
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https
GlobeNewswire · 09/21 14:51
MFA, TCOM, AVDL and TLSA among after-hours movers
Gainers: [[NTN]] +18.6%. [[AVDL]] +13.6%. [[GRIN]] +5.2%. [[PHAS]] +5%. [[MFA]] +5%.Losers: [[ACET]] -10.7%. [[TLSA]] -8.1%. [[TCOM]] -7.1%. [[JW.A]] -5.3%. [[ARAY]] -4.9%.
Seekingalpha · 09/18 21:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLSA. Analyze the recent business situations of TIZIANA LIFE SCIENCES PLC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLSA stock price target is 11.00 with a high estimate of 11.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 3.55M
% Owned: 9.28%
Shares Outstanding: 38.29M
TypeInstitutionsShares
Increased
3
85.68K
New
5
434.68K
Decreased
1
388
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TLSA
Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tiziana Life Sciences PLC stock information, including NASDAQ:TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.